前へ
次へ

Corporate Profile

Biocomo Incorporation is engaged in development of innovative biological vaccines.
Its missions are to create infectious vaccines that the human being have not overcome such as RSV and Ebola and to create most efficient, cost effective and safe cancer vaccines utilizing its high immunogenicity characteristics.

more

Technology

BC-PIV is our core platform technology which was named after our corporate name, BioComo and our leading vaccine carrier is derived from the recombinant human parainfluenza virus 2 (hPIV2) vectors.

more

Pipeline

Biocomo can offer specific candidates in infectious vaccines and cancer vaccines.

more

Information

2021-3-12
New patent application for Coronavirus (SARS-CoV-2) Vaccine using BC-PIV vector has been filed(pdf)
2021-2-23
BioComo and Mie University announce initiation of joint development of vaccines for SARS-CoV-2 variants using BC-PIV vector(pdf)
2021-2-18
BioComo announces that MediciNova has not been granted exclusive worldwide rights to use BC-PIV for SARS-CoV-2 vaccine from BioComo and Mie University yet (pdf)
2020-9
Notice of Strong Induction of Neutralizing Antibody Against Respiratory Syncytial Virus with BC-PIV Vector BasedVaccines In Mice
2020-7
Joint Development of SARS-CoV-2 Vaccine with MediciNova, Inc.
2020-3
Notice of embarking on SARS-CoV-2 vaccine development (pdf)
2020-2
Scrip features BC-PIV based new anti-tumor TNFRSF Signal Activator entitled “Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology”
https://scrip.pharmaintelligence.informa.com/SC141702/Japans-BioComo-Pursues-Novel-Ligand-Approach-To-ImmunoOncology
2019-10
New Immuno-oncology treatment, anti-tumor TNFRSF Signal Activator was introduced at Japan Healthcare Venture Summit 2019 (Bio Japan) in Yokohama
2019-8
BioComo’s Principal Scientist, Junpei Ohtsuka, Ph.D. published a scientific paper entitled “A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector (2019) 9:12901” as a lead author at Scientific Reports
2019-6
New Immuno-oncology treatment, anti-tumor TNFRSF Signal Activator was introduced at BIO2019 (Philadelphia)
2018-10
New Immuno-oncology treatment enhanced by NK/Tcell activity was introduced at Japan Healthcare Venture Summit 2018 (Bio Japa) in Yokohama (summary is linked here)
2018-05
Recently developed new pipeline products using BC-PIV platform in infectious vaccines (RSV, Zika and Ebola) and in cancer immunotherapy activating T cells will be presented at JETRO booth of BIO 2018 in Boston.
2017-10
Biocomo will present a poster, titled as “A structure based vaccine by a non-transmissible human parainfluenza virus vector” at 2017 International Society for Vaccines (ISV) Annual Congress at the Institute Pasteur in Paris on October 5th ? 7th
2017-07
The US patent, titled as “Vaccine Prepared Utilizing Human Parainfluenza Virus Type 2 Vector” was granted on June 4, 2017
2017-06
The European Patent titled as “method for producing virus vector gene transfer” was granted on June 14, 2017.
2016-07
The US patent, titled as “Vaccine Prepared Utilizing Human Parainfluenza Virus Type 2 Vector” was granted on June 4, 2017
2016-01
Biocomo participated in Biotech Showcase in San Francisco
2015-11
BioComo exhibited at Bio Europe.
2015-10
Bioomo exhibited at Bio Japan.
Page Top